文献

PA007276.r2a: Syd Labs体内实验级重组抗小鼠CD137 (TNFRSF9 or 4-1BB)单克隆抗体(克隆号3H3) ，大鼠IgG2a Kappa

3H3 抗体可结合 4-1BB（TNFRSF9 或 CD137），后者是肿瘤坏死因子受体（TNF受体）家族中具有代表性的共刺激受体。4-1BB 蛋白在多种细胞类型中表达，包括活化的 T 细胞、NK 细胞、树突状细胞（DC）、B 细胞、单核细胞和中性粒细胞。抗 4-1BB 诱导的 CD8+ T 细胞应答在抗肿瘤免疫中发挥主导作用，具体表现为诱导 CD8+ T 细胞释放更多效应分子、促进 CD8+ T 细胞增殖并减少其凋亡。

抗小鼠 CD137 (4-1BB) 单克隆抗体（克隆号：3H3）参考文献：

1. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.

Qi, et al. Nat Commun. 2019 May 17;10(1):2141. PMID: 31101822

“The co-stimulatory receptor 4-1BB (CD137) is a major target for cancer immunotherapy due to its ability to enhance T cell-mediated anti-tumor responses. … Here, we demonstrate that optimizing the balance between agonistic strength and FcγR binding affinity is critical to maximizing therapeutic efficacy. … These findings suggest a design strategy for developing safer and more effective anti-4-1BB antibodies, like clone 3H3, with minimized systemic toxicities.”

2. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.

Bukczynski, et al. J Virol. 2007 Mar;81(6):2711-24. PMID: 17182681

“In this study, we investigated the potential of co-stimulatory agonists targeting 4-1BB and OX40 to enhance vaccine-induced T-cell immunity. … We show that administration of agonistic anti-4-1BB (clone 3H3) and anti-OX40 antibodies during vaccination dramatically increases both CD4+ and CD8+ T-cell responses. … These results highlight the synergistic potential of combining co-stimulatory pathway activation with viral vector-based vaccine regimens to achieve robust protective immunity.”

3. Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation.

Hotz, et al. J Immunother Cancer. 2024 Jan 11;12(1):e008124. PMID: 38217311

“Bispecific antibodies targeting both tumor antigens and co-stimulatory receptors represent a promising class of cancer immunotherapeutics. … We designed mRNA-encoded bispecific molecules that facilitate polyclonal T cell engagement alongside PD-L1-dependent 4-1BB (CD137) costimulation. … This approach restricts 4-1BB activation to the tumor microenvironment, mimicking the localized efficacy of clones like 3H3 while eliminating systemic safety liabilities.”

4. TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation.

Takuya, et al. Cell Rep. 2023 Nov 28;42(11):113354. PMID: 37924248

“CD137 (4-1BB) is typically considered a co-stimulatory molecule that acts in concert with T-cell receptor (TCR) activation. … We demonstrate that TCR-independent CD137 signaling can directly drive the proliferation and terminal differentiation of exhausted CD8+ T cells in chronic viral or tumor settings. … These results reveal a novel role for CD137 agonists, such as the 3H3 clone, in reviving exhausted T-cell populations independently of antigen recognition.”

5. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.

Hoves, et al. Clin Cancer Res. 2020 May 15;26(10):2310-2321. PMID: 32156742

“Agonistic antibodies targeting CD137 (4-1BB) have shown powerful antitumor effects in preclinical models, but clinical development has been hindered by severe liver toxicity. … Here, we present a differentiated agonistic antibody that achieves robust antitumor efficacy and eradicates large established tumors. … Crucially, this therapeutic approach avoids systemic hepatotoxicity, establishing a wider therapeutic window for clinical applications of CD137-targeting agents.”

了解更多抗小鼠CD137 (TNFRSF9 or 4-1BB)单克隆抗体（clone：3H3）引用文献，请查看：抗小鼠CD137抗体（克隆号3H3）引用文献

Syd Labs抗小鼠CD137(TNFRSF9 or 4-1BB)重组抗体（克隆号3H3），大鼠IgG2a Kappa（货号：PA007276.r2a）推荐同型对照抗体:

重组大鼠IgG2a同型对照抗体，体内实验级（In vivo Grade Recombinant Rat IgG2a Isotype Control Antibody）